Paul J. Lytle
2017
In 2017, Paul J. Lytle earned a total compensation of $702.7K as Chief Financial Officer at Peregrine Pharmaceuticals, a 7% decrease compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $140,970 |
|---|---|
| Option Awards | $104,750 |
| Salary | $405,000 |
| Other | $51,948 |
| Total | $702,668 |
Lytle received $405K in salary, accounting for 58% of the total pay in 2017.
Lytle also received $141K in non-equity incentive plan, $104.8K in option awards and $51.9K in other compensation.
Rankings
In 2017, Paul J. Lytle's compensation ranked 10,596th out of 14,666 executives tracked by ExecPay. In other words, Lytle earned more than 27.8% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,596 out of 14,666 | 28th |
Division Manufacturing | 4,126 out of 5,772 | 29th |
Major group Chemicals And Allied Products | 1,473 out of 2,075 | 29th |
Industry group Drugs | 1,204 out of 1,731 | 30th |
Industry Pharmaceutical Preparations | 936 out of 1,333 | 30th |
Source: SEC filing on August 17, 2018.
Lytle's colleagues
We found three more compensation records of executives who worked with Paul J. Lytle at Peregrine Pharmaceuticals in 2017.